CYTK
Cytokinetics, Incorporated
NASDAQ · Healthcare · Biotechnology · US
$72.72
−1.66%Aug 28, 2026, 09:45 UTC
Cytokinetics announced positive primary results from the ACACIA-HCM Phase 3 trial of aficamten in non-obstructive hypertrophic cardiomyopathy, presented at the ESC Congress 2026 and published in The New England Journal of Medicine, meeting both dual primary endpoints.
Aug 18, 2026, 20:00 UTC
Cytokinetics granted stock options for 27,565 shares and 18,273 restricted stock units to 12 new employees as inducement grants on August 14, 2026.
Source:Aug 17, 2026, 11:57 UTC
Cytokinetics announced plans to file for a new indication for MYQORZO in non-obstructive hypertrophic cardiomyopathy before the end of 2026.
Source:Aug 13, 2026, 13:31 UTC
Cytokinetics filed a patent infringement lawsuit against Bristol-Myers Squibb.
Source:Aug 6, 2026, 22:41 UTC
Cytokinetics reported a second-quarter loss of $1.5 per share, beating the Zacks Consensus Estimate of a loss of $1.63, and compared to a loss of $1.12 per share a year ago.
Jul 30, 2026, 09:46 UTC
The United Kingdom approved Cytokinetics' drug MYQORZO for the treatment of heart disease.
Jun 1, 2026, 11:30 UTC
Cytokinetics launched MYQORZO (aficamten) commercially in Germany for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
Source: